Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High Dose IL-2 and SABR for Metastatic Clear Cell Renal Cell Cancer
NCT01896271Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Oct 2013
- Primary completion
- Aug 2020
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in clear cell renal cell carcinoma (ccRCC), sponsored by UT Southwestern Medical Center. Started Oct 2013; status: completed.
02
Drugs
aldesleukin
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT01896271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01896271.